Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1999-02-12
1999-11-09
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514469, 549220, 549468, A61K 3134, C07D30780, C07F 906
Patent
active
059815140
ABSTRACT:
Disclosed herein are compounds of the formula ##STR1## or the pharmaceutically acceptable salts thereof wherein R.sub.1 is alkyl of 1-6 carbon atoms;
REFERENCES:
patent: 3248401 (1966-04-01), Tondeur et al.
patent: 4235871 (1980-11-01), Paphadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4837028 (1989-06-01), Allen
patent: 5234949 (1993-08-01), Ehrenpreis et al.
Andreasen, F. et al., Pharmacokinetics of amiodarone after intravenous and oral administration, Eur. J. Clin. Pharmacol., 19(4):293-299 (1981).
Banitt, E.H. et al., Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides, J. Med. Chem., 20(6):821-826 (1977).
Bopp et al., Acute hemodynamic effects of intravenous amiodarone in patients with coronary artery disease, J. Cardio. Pharmacol., 7:286-289 (1985).
Casalini, C. et al., Metabolites and analogs of 2-ethyl-2,3-dihydro-5-benzofuranacetic acid (furofenac): chemical and pharmacological properties, J. Pharm. Sci., 69(2):164-167 (1980).
Cullis, P.R. et al., Liposomes as Pharmaceuticals, Liposomes, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, pp. 39-72 (1987).
Escoubet, B. et al., Suppression of Arrhythmias Within Hours After Single Oral Dose of Amiodarone and Relation to Plasma and Myocardial Concentrations, Am. J. Cardiol., 55:696-702 (1985).
Gough et al., Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs, Journal of Cardiovascular Pharmacology, 4:375-380 (1982).
Gregoriadis, Liposomes for drugs and vaccines, Trends in Biotechnology, 3(9):235-241 (1985).
Gruner, S.M., Materials Properties of Liposomal Bilayers, Liposomes, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, pp. 1-38 (1987).
Kadish et al., The Use of Intravenous Amiodarone in the Acute Therapy of Life-Threatening tachyarrhythmias, Progress in Cardiovascular Diseases, 31:4, 281-294 (1989).
Kato, R. et al., Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone: comparison with amiodarone during chronic administration in rabbits, Am. Heart J., 115(2):351-359 (1988).
Kodama, I. et al., Cellular electropharmacology of amiodarone. Cardiovasc. Res., 35(1):13-29 (1997).
Kosinzki, et al., Hemodynamic effects of intravenous amiodarone, J. Am. Coll. Card., 4:565-70 (1984).
Leppik, I.E. et al., Phenytoin prodrug: preclinical and clinical studies, Epilepsia, 30 Suppl. 2:S22-S26 (1989).
Morady et al., Intravenous Amiodarone in the Acute Treatment of Recurrent Symptomatic Ventricular Tachycardia, Am. J. Cardiol., 51:156-159 (1983).
Mostow et al., Rapid Suppression of Complex Ventricular Arrhythmias With High-Dose Oral Amiodarone, Circulation, 73:1231-1238 (1986).
Nattel, S., Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite, J. Cardiovasc. Pharmacol., 8(4):771-777 (1986).
Nattel et al., The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction, Circulation, 77(1):200-208 (1988).
Ortiz de Montellano, P.R., Biotransformations of Drugs and Chemicals, Molecular biology and biotechnology: a comprehensive desk reference, Meyers, VCH Publishers, New York, 117-120 (1995).
Physicians' Desk Reference, 1992, p. 2446 under tradename Cordarone(r).
Remington: Practice of The Science and Pharmacy, Gennaro, Mack Publishing, Eaton, 717-718, (1995).
Remington: Practice of The Science and Pharmacy, Gennaro, Mack Publishing, Eaton, 959 (1995).
Remme et al., Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function, Am. Heart J., 122:96-103 (1991).
Riva, E. et al., Anti-arrhythmic effects of amiodarone and desethylamiodarone on malignant ventricular arrhythmias arising as a consequence of ischaemia and reperfusion in the anaesthetised rat, Cardiovasc. Res., 23(4):331-339 (1989).
Saksena, S. et al., Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia, Am. J. Cardiol., 54(3):347-352 (1984).
Singh, B.N., Amiodarone: historical development and pharmacologic profile, Am. Heart J., 106(4 Pt 2):788-797 (1983).
Talajic, M. et al., Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite, Circulation, 75(1):265-271 (1987).
Torres-Arrault et al., Electrophysiologic effects of Tween 80 in the myocardium and specialized conduction system of the canine heart, Journal of Electrocardiology, 17(2):145-152 (1984).
Varia, S.A. et al., Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use, J. Pharm. Sci., 73(8):1068-1073 (1984).
Varia, S.A. et al., Phenytoin prodrugs IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters, J. Pharm. Sci., 73(8):1074-1080 (1984).
Varia, S.A. et al., Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs, J. Pharm. Sci., 73(8):1080-1087 (1984).
Varia, S.A. et al., Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats, J. Pharm. Sci., 73(8):1087-1090 (1984).
Venkatesh, N. et al., Effects of amiodarone and desethylamiodarone on rabbit myocardial beta-adrenoceptors and serum thyroid hormones--absence of relationship to serum and myocardial drug concentrations, J. Cardiovasc. Pharmacol., 8(5):989-997 (1986).
Wellens, H.J. et al., A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient, Circulation, 69(1):120-124 (1984).
Zhou, L. et al., Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold, J. Am. Coll. Cardiol., 31(7):1672-1678 (1998).
Richter Johann
Solola Taofiq A.
LandOfFree
(N-alkyl-N-hydroxymethylamino)alkoxybenzoylbenzofurans and the p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (N-alkyl-N-hydroxymethylamino)alkoxybenzoylbenzofurans and the p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (N-alkyl-N-hydroxymethylamino)alkoxybenzoylbenzofurans and the p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456130